Edwards Lifesciences (EW) PT Raised to at Jefferies Following PARTNER II Sapien 3 Data

Northland Capital Markets Downgrades Edwards Lifesciences (EW) to Market Perform (Earlier)

Northland Capital Markets downgraded Edwards Lifesciences (NYSE: EW) from Outperform to Market Perform with a price target of $105.00.

Aanalyst Suraj Kalia commented, "PARTNER-2 intermediate-risk cohort showed that SAPIEN-3 was superior to surgery @ 1-yr in the composite endpoint of all-cause death, stroke and moderate... More

Stifel Raises Price Target on Edwards Lifesciences (EW) to $117; Reiterates Buy

Stifel reiterated a Buy rating on Edwards Lifesciences (NYSE: EW), and raised the price target to $117.00 (from $98.00), following data presentations at American College of Cardiology. Given the outstanding data, Stifel is increasing its 2016-2020 revenue and EPS projections. On EPS, they now project 2016 at $2.67, up $0.06 from prior estimates and 2017 moves to $3.36, up $0.36 or 12% vs prior projection.

Analyst Rick Wise... More

Edwards Lifesciences (EW) Raising Estimates, PT on Better Than Expected Sapien 3 Data - Leerink Partners

Leerink Partners analyst, Danielle Antalffy, raised her PT on Edwards Lifesciences by nearly 25% to $115 to account for better than expected Sapien 3 intermediate risk data. No change to Outperform rating.

Sapien 3 is demonstrating significant superiority vs. surgery in intermediate risk patients which drives estimates higher while still leaving meaningful room for upside. Given the positive Sapien 3 data in intermediate risk patients -- which demonstrated superiority vs.... More

BTIG Upgrades Edwards Lifesciences (EW) to Buy

BTIG upgraded Edwards Lifesciences (NYSE: EW) from Neutral to Buy with a price target of $115. The upgrade follows strong SAPIEN 3... More

Edwards Lifesciences (EW) PT Raised to $98 at Credit Suisse Following Sapien Data

Credit Suisse analyst M. Keeler raised its price target on Outperform-rated Edwards Lifesciences (NYSE: EW) to $98.00 (from $88.00) after 1 year Sapien 3 TAVI data in intermediate risk patients showed TAVI to be superior vs. surgery on a primary endpoint of mortality, stroke or moderate to severe... More

Edwards Lifesciences' (EW) SAPIEN XT PARTNER II Trial Met Primary Endpoint

Edwards Lifesciences Corporation (NYSE: EW) announced that the randomized PARTNER II Trial comparing the SAPIEN XT valve to surgery in intermediate-risk patients successfully achieved its primary endpoint at two years. The results of the study were presented as part of the late-breaking clinical trials at the American College of Cardiology's 65th Annual Scientific Session (ACC.16) in Chicago, and simultaneously published online in The New England Journal of Medicine.

The PARTNER II Trial is the first randomized clinical trial comparing outcomes of severe, symptomatic aortic stenosis patients who were at intermediate risk for... More

Edwards Lifesciences (EW) Announces Strong SAPIEN 3 TAVR Data vs. Surgery

Edwards Lifesciences Corporation (NYSE: EW) announced that new data on patients at intermediate risk for open-heart surgery demonstrated that transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve was superior to surgery at one year on a composite primary endpoint of mortality, stroke and moderate or severe aortic regurgitation. In addition, the SAPIEN 3 valve demonstrated clinical superiority at one year on individual assessments of all-cause mortality and of stroke. The results of the study of 1,078 enrolled patients with severe, symptomatic aortic stenosis were presented as part of the late-breaking clinical trials at the American College... More

Edwards Lifesciences (EW) Catalyst: ACC Meeting

UBS's Edwards Lifesciences (NYSE: EW) analyst, Matt Miksic performed a historical event analysis of 10 late breaking clinical trials over the past 10 years and found that the positive impact of late-breaking clinical data is rarely reflected in stocks until after it hits the tape. Specifically, stocks... More